Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement
News Aug 21, 2009
Omnia Biologics, Inc. and Aparna Biosciences Corp. have announced a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.
“Despite recent setbacks in lentivirus based drug development on the business side, we continue to see great promise in the platform.” Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc. commented on the deal. “The AparnaBio team has deep experience, a level of sophistication and a track record of success that gives them a leg up on successfully executing on the commercial potential of the lentivirus drug delivery concept. We are pleased to be chosen by AparnaBio as a partner in this development effort.”
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE